Stocks · News reference

Climb Bio Says Single 320 mg CLYM116 Dose Suppressed APRIL Over 90%, IgA 60-75% Through 12 Weeks In Phase 1 Healthy Volunteers; Sees Phase 2 IgA Nephropathy Data H1 2027

Sep 3, 2026, 11:07 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 2, 2026, 1:33 PMBenzinga Newsdesk
Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and
CLYM
BenzingaSep 8, 2026, 4:55 PMBenzinga Newsdesk
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
CLYM
BenzingaSep 8, 2026, 1:07 PMAvi Kapoor
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
ABNB APP BNTX CLYM CPB
BenzingaSep 8, 2026, 11:21 AMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.
CLYM